Home › Companies › Avadel Pharmaceuticals Plc › 2024-2025
Compiled from SEC Form N-PX filings and Avadel Pharmaceuticals Plc’s Form 8-K, filed 2024-08-01 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Proxy season: 2024-2025 2025-2026
Explore Avadel Pharmaceuticals Plc in the interactive database Compare manager voting policies
These tallies are Avadel Pharmaceuticals Plc’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-08-01 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Gregory J. Divis | 48,809,808 | 4,581,316 | -- | 37,580 | 18,770,680 | Majority: yes |
| Elect Director: Dr. Eric J. Ende | 47,813,619 | 5,572,208 | -- | 42,877 | 18,770,680 | Majority: yes |
| Elect Director: Geoffrey M. Glass | 48,119,067 | 5,266,257 | -- | 43,380 | 18,770,680 | Majority: yes |
| Elect Director: Dr. Mark A. McCamish | 48,811,358 | 4,576,847 | -- | 40,499 | 18,770,680 | Majority: yes |
| Elect Director: Linda S. Palczuk | 48,128,173 | 5,258,040 | -- | 42,491 | 18,770,680 | Majority: yes |
| Elect Director: Peter J. Thornton | 48,823,282 | 4,562,281 | -- | 43,141 | 18,770,680 | Majority: yes |
| Elect Director: Dr. Naseem S. Amin | 48,738,654 | 4,646,143 | -- | 43,907 | 18,770,680 | Majority: yes |
| Proposal 2: To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2024, and to authorize, in a binding vote, the A | 70,739,385 | 1,299,493 | 160,506 | -- | 0 | Majority: yes |
| Proposal 3: To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Proxy Statement. | 47,961,536 | 5,105,188 | 361,980 | -- | 18,770,680 | Majority: yes |
Source: Avadel Pharmaceuticals Plc, Form 8-K, filed with the SEC on 2024-08-01 — read the filing on EDGAR.
Each item below shows how the 134 asset managers that disclosed a Avadel Pharmaceuticals Plc vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 9 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Avadel Pharmaceuticals Plc’s own tally for this item (“Proposal 3: To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Proxy Statement.”): 47,961,536 for, 5,105,188 against, per its Form 8-K filed 2024-08-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,204,000 outstanding shares: 49.9% for, 5% against (55% of the company cast a for/against vote).
The 133 asset managers below cast 87% of the shares they voted on this item FOR (37,932,558 for, 5,760,293 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 12,815,946 | 0 | 0 | 0 | For |
| GENDELL JEFFREY L | 0 | 5,740,143 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 3,972,099 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 2,776,539 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 1,397,507 | 0 | 0 | 0 | For |
| UniSuper Management Pty Ltd | 948,907 | 0 | 0 | 0 | For |
| Woodline Partners LP | 926,109 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 883,247 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 664,738 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT PARTNERS, LP | 659,931 | 0 | 0 | 0 | For |
| Tri Locum Partners LP | 592,699 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 541,272 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 478,255 | 0 | 0 | 0 | For |
| NEW YORK STATE COMMON RETIREMENT FUND | 445,191 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| Utah Retirement Systems | 410,284 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 384,784 | 0 | 0 | 0 | For |
| Goldman Sachs | 351,760 | 0 | 0 | 0 | For |
| Knott David M Jr | 333,000 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 294,077 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 287,008 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 0 | 280,000 | 0 | Abstain |
| Obermeyer Wealth Partners | 279,494 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
Showing the 25 largest of 133 asset managers. See all 133 in the interactive database.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Avadel Pharmaceuticals Plc’s own tally for this item (“Proposal 2: To ratify, on a non-binding advisory basis, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2024, an”): 70,739,385 for, 1,299,493 against, per its Form 8-K filed 2024-08-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,204,000 outstanding shares: 74% for, 1% against (75% of the company cast a for/against vote).
The 20 asset managers below cast 100% of the shares they voted on this item FOR (5,857,585 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| RBB Fund Trust | 45,054 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Dr. Eric J. Ende”): 47,813,619 for, 5,572,208 against, per its Form 8-K filed 2024-08-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,204,000 outstanding shares: 49.7% for, 6% against (55% of the company cast a for/against vote).
The 19 asset managers below cast 99.8% of the shares they voted on this item FOR (5,804,656 for, 7,875 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 0 | 4,190 | 0 | 0 | Against |
| State Street | 0 | 3,685 | 0 | 0 | Against |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Dr. Mark A. McCamish”): 48,811,358 for, 4,576,847 against, per its Form 8-K filed 2024-08-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,204,000 outstanding shares: 50.7% for, 5% against (55% of the company cast a for/against vote).
The 19 asset managers below cast 100% of the shares they voted on this item FOR (5,812,531 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Dr. Naseem S. Amin”): 48,738,654 for, 4,646,143 against, per its Form 8-K filed 2024-08-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,204,000 outstanding shares: 50.7% for, 5% against (55% of the company cast a for/against vote).
The 19 asset managers below cast 100% of the shares they voted on this item FOR (5,812,531 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Geoffrey M. Glass”): 48,119,067 for, 5,266,257 against, per its Form 8-K filed 2024-08-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,204,000 outstanding shares: 50.1% for, 5% against (55% of the company cast a for/against vote).
The 19 asset managers below cast 99.9% of the shares they voted on this item FOR (5,808,341 for, 4,190 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 0 | 4,190 | 0 | 0 | Against |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Gregory J. Divis”): 48,809,808 for, 4,581,316 against, per its Form 8-K filed 2024-08-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,204,000 outstanding shares: 50.7% for, 5% against (55% of the company cast a for/against vote).
The 19 asset managers below cast 100% of the shares they voted on this item FOR (5,812,531 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Linda S. Palczuk”): 48,128,173 for, 5,258,040 against, per its Form 8-K filed 2024-08-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,204,000 outstanding shares: 50.1% for, 5% against (55% of the company cast a for/against vote).
The 19 asset managers below cast 99.9% of the shares they voted on this item FOR (5,808,341 for, 4,190 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 0 | 4,190 | 0 | 0 | Against |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Avadel Pharmaceuticals Plc’s own tally for this item (“Elect Director: Peter J. Thornton”): 48,823,282 for, 4,562,281 against, per its Form 8-K filed 2024-08-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,204,000 outstanding shares: 50.7% for, 5% against (55% of the company cast a for/against vote).
The 19 asset managers below cast 100% of the shares they voted on this item FOR (5,812,531 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 4,629,164 | 0 | 0 | 0 | For |
| DWS | 421,000 | 0 | 0 | 0 | For |
| BRANDES INVESTMENT TRUST | 273,202 | 0 | 0 | 0 | For |
| Lord Abbett | 85,516 | 0 | 0 | 0 | For |
| Russell Investments | 63,365 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 62,753 | 0 | 0 | 0 | For |
| Fidelity | 45,690 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 42,258 | 0 | 0 | 0 | For |
| Royce | 35,460 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 34,030 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 31,765 | 0 | 0 | 0 | For |
| Equitable | 30,640 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 21,626 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 12,677 | 0 | 0 | 0 | For |
| Empower | 8,120 | 0 | 0 | 0 | For |
| ProShares | 5,893 | 0 | 0 | 0 | For |
| BlackRock | 4,190 | 0 | 0 | 0 | For |
| State Street | 3,685 | 0 | 0 | 0 | For |
| Portside Wealth Group, LLC | 1,497 | 0 | 0 | 0 | For |
Ranked by the number of Avadel Pharmaceuticals Plc shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 96,204,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 13.32% |
| 2 | GENDELL JEFFREY L | 5.97% |
| 3 | JANUS INVESTMENT FUND | 4.81% |
| 4 | Vivo Capital, LLC | 4.13% |
| 5 | BRAIDWELL LP | 2.89% |
| 6 | RTW INVESTMENTS, LP | 1.45% |
| 7 | UniSuper Management Pty Ltd | 0.99% |
| 8 | Woodline Partners LP | 0.96% |
| 9 | MPM BioImpact LLC | 0.92% |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.69% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 5.67% | 13F |
| Jeffrey L. Gendell | 5.03% | 13G |
| Vanguard Group | 4.06% | 13F |
| Citadel Advisors | 2.50% | 13F |
| JANUS HENDERSON GROUP PLC | 1.90% | 13G |
| State Street | 1.72% | 13F |
| Geode Capital | 1.24% | 13F |
| Morgan Stanley | 1.08% | 13F |
| Goldman Sachs | 0.76% | 13F |
| Northern Trust | 0.67% | 13F |
Percentages above are of 96,204,000 shares outstanding, as reported by Avadel Pharmaceuticals Plc on its Form 10-Q dated 2024-06-30 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Avadel Pharmaceuticals Plc’s 10-Q dated 2024-06-30. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Avadel Pharmaceuticals Plc's shareholder meeting held 2024-07-30, in the 2024-2025 proxy season, 134 asset managers reported how they voted on 9 ballot items in their SEC Form N-PX filings, covering 358 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the named executive officers… — FOR was 90% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Avadel Pharmaceuticals Plc's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-08-01.
Avadel Pharmaceuticals Plc proxy season coverage: 2024-2025 (this page) · 2025-2026.